Objective: The aim of this study is to investigate the association between Cathepsin B and Parkinson’s Disease (PD), with a particular focus on determining the role of N-acetylaspartate as a potential mediator. Methods: We used summary-level data from Genome-Wide Association Studies (GWAS) for a two-sample Mendelian randomization (MR) analysis, exploring the association between Cathepsin B (3301 cases) and PD (4681 cases). A sequential two-step MR approach was applied (8148 cases) to study the role of N-acetylaspartate. Results: The MR analysis yielded that genetically predicted elevated Cathepsin B levels correlated with a reduced risk of developing PD (p = 0.0133, OR: 0.9171, 95% CI: 0.8563–0.9821). On the other hand, the analysis provided insufficient evidence to determine that PD affected Cathepsin B levels (p = 0.8567, OR: 1.0035, 95% CI: 0.9666–1.0418). The estimated effect of N-acetylaspartate in this process was 7.52% (95% CI = −3.65% to 18.69%). Conclusions: This study suggested that elevated Cathepsin B levels decreased the risk of developing PD, with the mediation effect of N-acetylaspartate. Further research is needed to better understand this relationship.
Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.
Background: Improving the treatment of lung adenocarcinoma (LUAD) requires urgent exploration of molecular mechanisms underlying its progression and new prognostic predictors due to low long-term survival rates. Carcinogenesis studies have highlighted the clinical implications of KLF4, a member of the Krüppel-like transcription factor family. In this study, we aimed to investigate the expression of KLF4 in LUAD, assess its correlation with clinicopathological characteristics, prognosis and tumor immune cell infiltration, and analyze its potential advantages as a prognostic marker for LUAD patients. Methods: This study examined KLF4 expression and clinical characteristics in normal and LUAD patients using TCGA and GEO datasets. 25 pairs of LUAD and normal tissues were then validated by IHC. Then we utilized analyses including PPI, GO, KEGG, GSEA and assessment of methylation status, to explore the potential mechanism of KLF4 in LUAD. Differences in the abundance of immune cell infiltration with high and low KLF4 expression were assessed by ssGSEA. Finally, univariate and multivariate Cox regression analysis were performed to construct a nomogram for evaluating the correlation between KLF4 expression and clinical prognosis. Results: KLF4 was downregulated among tumors compared with normal tissue in multiple LUAD cohorts (P < 0.001). KLF4-related genes were then identified through differential analysis, and functional annotation revealed its significant enrichment in the processes of cornification and peptidase activity. GSEA indicated a potential involvement of KLF4 in tumor immunoregulation. Further analysis revealed a significant correlation between the expression of KLF4 and the infiltration levels of neutrophils, mast cells, eosinophils, and NK CD56bright cells (P < 0.001). Additionally, KLF4 in LUAD was found associated with a wide range of immune markers. Notably, higher level of KLF4 significantly reduced prognostic factors including OS, DSS and PFI. Finally, a nomogram incorporating KLF4, pathologic T and N stage, and residual tumor was built and exhibited promising predictive power for assessing the survival outcomes of LUAD patients. Conclusion: High expression of KLF4 is an independent adverse prognostic factor in LUAD, and is strongly associated with aggressive clinical features and unfavorable immune infiltration. Therefore, KLF4 can be used as a novel prognostic biomarker for predicting patient outcomes.